Joaquim Mullol

Q: What Schools Are Affiliated With Joaquim Mullol

Joaquim Mullol is affiliated with the following schools: University of California, Berkeley, Tohoku University, Stanford University, Georgetown University, University of Barcelona

Joaquim Mullol's AcademicInfluence.com Rankings

Joaquim Mullol

Philosophy

#6511

World Rank

#9556

Historical Rank

Logic

#3664

World Rank

#4858

Historical Rank

philosophy Degrees

Joaquim Mullol

Biology

#8840

World Rank

#11974

Historical Rank

Computational Biology

#169

World Rank

#170

Historical Rank

Genetics

#890

World Rank

#986

Historical Rank

Molecular Biology

#1149

World Rank

#1175

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Joaquim Mullol's Degrees

Bachelors Biology University of Barcelona
Masters Genetics University of Barcelona
PhD Molecular Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Joaquim Mullol Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joaquim Mullol's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * (2008) (3261)
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision (2017) (1029)
Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. (2016) (668)
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. (2016) (596)
[European position paper on rhinosinusitis and nasal polyps group]. (2008) (567)
European position paper on rhinosinusitis and nasal polyps 2007. (2007) (538)
Practical guide to skin prick tests in allergy to aeroallergens (2012) (532)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (2019) (454)
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (2008) (446)
EAACI Position Paper on Rhinosinusitis and Nasal Polyps Executive Summary (2005) (381)
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) (351)
EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. (2007) (326)
Positioning of antihistamines in the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (2012) (296)
EPOS European Position Paper on Rhinosinusitis and Nasal Polyps 2007 [pocket guide] (2007) (255)
Viruses and bacteria in acute asthma exacerbations – A GA2LEN‐DARE* systematic review (2010) (252)
Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. (1999) (234)
Local allergic rhinitis: concept, pathophysiology, and management. (2012) (229)
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. (2012) (224)
A survey of the burden of allergic rhinitis in Europe. (2008) (215)
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. (2004) (208)
Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper (2018) (203)
Expression of glucocorticoid receptor α- and β-isoforms in human cells and tissues (2002) (202)
Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. (2006) (196)
International consensus statement on allergy and rhinology: rhinosinusitis 2021 (2020) (190)
Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments (2005) (188)
Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. (2019) (188)
Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. (2020) (188)
Diagnostic tools in Rhinology EAACI position paper (2011) (179)
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper (2008) (178)
MACVIA‐ARIA Sentinel NetworK for allergic rhinitis (MASK‐rhinitis): the new generation guideline implementation (2015) (178)
Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study) (2012) (171)
Non‐allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology (2017) (168)
EUFOREA consensus on biologics for CRSwNP with or without asthma (2019) (159)
Measurement of cell microrheology by magnetic twisting cytometry with frequency domain demodulation. (2001) (158)
Transforming Growth Factor-β1 Gene Polymorphisms Are Associated with Disease Progression in Idiopathic Pulmonary Fibrosis (2003) (156)
ICON: chronic rhinosinusitis (2014) (156)
Substance P and neurokinin A in human nasal mucosa. (1991) (152)
Rupatadine in allergic rhinitis and chronic urticaria (2008) (151)
EAACI Position paper on the standardization of nasal allergen challenges (2018) (149)
Requirements for medications commonly used in the treatment of allergic rhinitis (2003) (148)
Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN) (2006) (142)
Air pollution and allergens. (2007) (141)
The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries (2020) (128)
MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. (2016) (128)
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle (2016) (124)
Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement (2020) (124)
Dietary micronutrients/antioxidants and their relationship with bronchial asthma severity (2001) (120)
Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues. (2002) (120)
Closure of cerebrospinal fluid leaks prevents ascending bacterial meningitis. (2005) (118)
2019 ARIA Care pathways for allergen immunotherapy (2019) (117)
Vasoactive intestinal peptide in human nasal mucosa. (1990) (115)
Expression of the human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone. (2001) (115)
Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. (2011) (114)
A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. (2007) (109)
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’ (2009) (108)
European position Papaer on Rhinosinusitis and Nasal Polyp 2007 (2007) (107)
Important research questions in allergy and related diseases: 3‐chronic rhinosinusitis and nasal polyposis – a GA2LEN study (2009) (107)
Barcelona Smell Test - 24 (BAST-24): validation and smell characteristics in the healthy Spanish population. (2006) (107)
A Short Course of Oral Prednisone Followed by Intranasal Budesonide Is an Effective Treatment of Severe Nasal Polyps (2006) (105)
Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report (2017) (102)
Mucin genes have different expression patterns in healthy and diseased upper airway mucosa (2006) (99)
Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry (2000) (98)
Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis (2013) (98)
Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. (2010) (98)
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. (2019) (98)
Efficacy of omalizumab in the treatment of nasal polyps (2010) (97)
Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (96)
Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (96)
Olfactory Dysfunction in Neurodegenerative Diseases (2018) (96)
Impairment of olfaction and mucociliary clearance after expanded endonasal approach using vascularized septal flap reconstruction for skull base tumors. (2013) (95)
Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (2016) (95)
Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA2LEN – ARIA Position Paper (2012) (93)
The antrochoanal polyp. (2004) (93)
Lack of efficacy of long‐term, low‐dose azithromycin in chronic rhinosinusitis: a randomized controlled trial (2011) (92)
Genetic aspects of allergic rhinitis. (2009) (91)
Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK‐rhinitis study (2017) (90)
Corticosteroid treatment in chronic rhinosinusitis: the possibilities and the limits. (2009) (90)
Allergic rhinitis and school performance. (2009) (88)
Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement (2020) (88)
Severe nasal polyposis and its impact on quality of life. The effect of a short course of oral steroids followed by long-term intranasal steroid treatment. (2005) (88)
Stress and allergy. (2009) (88)
Glucocorticoid receptors in human airways (2004) (87)
The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey (2015) (87)
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology (2019) (87)
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology (2019) (87)
MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence (2018) (87)
Allergic Rhinitis and its Impact on Asthma update (ARIA 2008). The perspective from Spain. (2008) (87)
MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence (2018) (87)
Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: The PEDRIAL study (2011) (86)
Treatment of allergic rhinitis using mobile technology with real‐world data: The MASK observational pilot study (2018) (86)
Chronic rhinosinusitis and nasal polyps: the role of generic and specific questionnaires on assessing its impact on patient’s quality of life (2008) (85)
Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper (2020) (83)
Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. (2019) (82)
Development and implementation of guidelines in allergic rhinitis – an ARIA‐GA2LEN paper (2010) (81)
Chronic Rhinosinusitis With Nasal Polyps and Asthma. (2020) (80)
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma (2019) (80)
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma (2019) (80)
Persistent allergic rhinitis has a moderate impact on the sense of smell, depending on both nasal congestion and inflammation (2009) (79)
The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study (2018) (78)
Comparative pharmacology of the H1 antihistamines. (2006) (77)
Olfactory dysfunction in the COVID-19 outbreak. (2020) (75)
Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. (2003) (75)
Eosinophil cationic protein stimulates and major basic protein inhibits airway mucus secretion. (1991) (75)
Costs associated with persistent allergic rhinitis are reduced by levocetirizine (2005) (73)
Tissue remodelling in upper airways: where is the link with lower airway remodelling? (2006) (73)
Comparison of the role of nasal polyp and normal nasal mucosal epithelial cells on in vitro eosinophil survival. Mediation by GM–CSF and inhibition by dexamethasone (1994) (73)
Nasal polyps in patients with asthma: prevalence, impact, and management challenges (2016) (73)
COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper (2020) (73)
Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control (2017) (72)
Alpha and beta glucocorticoid receptors: Relevance in airway diseases (2007) (70)
Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps. (2002) (70)
Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe (2011) (70)
Glucocorticoid Receptor Isoforms α and β in in Vitro Cytokine-induced Glucocorticoid Insensitivity (2004) (69)
Work productivity in rhinitis using cell phones: The MASK pilot study (2017) (69)
The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study (2009) (69)
Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). (2008) (69)
Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis (2006) (69)
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study (2018) (68)
Comparative Analysis of Allergic Rhinitis in Children and Adults (2013) (68)
United airways again: high prevalence of rhinosinusitis and nasal polyps in bronchiectasis (2009) (68)
Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. (2013) (66)
Smell and taste dysfunctions in COVID-19 are associated with younger age in ambulatory settings - a multicenter cross-sectional study. (2020) (66)
Neuropeptide Y (NPY) in human nasal mucosa. (1990) (66)
Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases (2019) (65)
H1 antihistamines: psychomotor performance and driving. (2006) (64)
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials (2020) (64)
Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. (1995) (63)
Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. (2004) (63)
Molecular diagnosis in allergology: application of the microarray technique. (2009) (62)
Development of an International Odor Identification Test for Children: The Universal Sniff Test (2018) (62)
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA 2 LEN paper (2010) (62)
From pollinosis to digestive allergy. (2009) (60)
Patient Perceptions of Allergic Rhinitis and Quality of Life: Findings From a Survey Conducted in Europe and the United States (2008) (60)
Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis (2012) (58)
Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study (2009) (58)
Effect of topical anti-inflammatory drugs on epithelial cell-induced eosinophil survival and GM-CSF secretion. (1997) (57)
Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study (2019) (56)
Oral plus nasal corticosteroids improve smell, nasal congestion, and inflammation in sino‐nasal polyposis (2014) (56)
The impact of asthma and aspirin sensitivity on quality of life of patients with nasal polyposis (2005) (56)
The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine (2004) (56)
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020) (2020) (55)
Calcitonin gene-related peptide in human nasal mucosa. (1990) (55)
United airways: the impact of chronic rhinosinusitis and nasal polyps in bronchiectasic patient’s quality of life (2009) (55)
Solitary Fibrous Tumour of the Nasal Cavity and Paranasal Sinuses (2003) (54)
Persistent asthma has an accumulative impact on the loss of smell in patients with nasal polyposis. (2011) (54)
Update on rupatadine in the management of allergic disorders (2015) (54)
Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. (2004) (54)
Electronic Clinical Decision Support System for allergic rhinitis management: MASK e‐CDSS (2018) (54)
Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids (2008) (53)
Antihistamines in the treatment of chronic urticaria. (2007) (53)
Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study (2012) (53)
Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA2LEN Study (2010) (53)
Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA (2016) (52)
Expression of the glucocorticoid receptor alpha and beta isoforms in human nasal mucosa and polyp epithelial cells. (2003) (52)
Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak (2020) (51)
Endothelin in human nasal mucosa. (1993) (51)
Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis (2020) (50)
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (2016) (49)
Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. (2006) (49)
Lipid and protein metabolism in asthma. Effects of diet and corticosteroid therapy (1999) (49)
The effect of neutrophil protenase enzymes on the release of mucus from feline and human airway cultures. (1994) (48)
Endothelin-1 induces GM-CSF, IL-6 and IL-8 but not G-CSF release from a human bronchial epithelial cell line (BEAS-2B) (1996) (48)
Chemosensory dysfunction in COVID-19 out-patients (2020) (47)
Comparison of human nasal mucosal secretion in vivo and in vitro. (1992) (47)
Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities (2018) (47)
Assessment of nasal obstruction: correlation between subjective and objective techniques. (2013) (47)
Self-reported Taste and Smell Disorders in Patients with COVID-19: Distinct Features in China (2020) (47)
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. (2019) (47)
Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: the ESPRINT questionnaire. (2007) (46)
Turner's syndrome and other forms of congenital hypogonadism impair quality of life and sexual function. (2013) (46)
Use of antihistamines in pediatrics. (2007) (45)
Overuse of diagnostic tools and medications in acute rhinosinusitis in Spain: a population-based study (the PROSINUS study) (2018) (45)
Expanded Endonasal Approach using Vascularized Septal Flap Reconstruction for Skull Base Tumors has a Negative Impact on Sinonasal Symptoms and Quality of Life (2013) (45)
In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson’s disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese‐enhanced magnetic resonance imaging in the 6‐hydroxydopamine rat model (2011) (45)
A survey of the burden of allergic rhinitis in Spain. (2009) (45)
Nuclear factor‐κB activity is down‐regulated in nasal polyps from aspirin‐sensitive asthmatics (2003) (44)
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project) (2018) (44)
Health‐related quality of life in allergic rhinitis: comparing the short form ESPRINT‐15 and MiniRQLQ questionnaires (2007) (44)
Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis (2006) (43)
Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort study. (2010) (43)
Placebo effect in clinical trials involving patients with allergic rhinitis. (2011) (42)
Role of Medical Therapy in the Management of Nasal Polyps (2012) (42)
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies (2020) (42)
Expression of glucocorticoid receptors α and β in steroid sensitive and steroid insensitive interstitial lung diseases (2004) (42)
ARIA guideline 2019: treatment of allergic rhinitis in the German health system (2019) (41)
Effects of topical anti‐inflammatory drugs on eosinophil survival primed by epithelial cells. Additive effect of glucocorticoids and nedocromil sodium (1997) (40)
Effect of desloratadine on epithelial cell granulocyte‐macrophage colony‐stimulating factor secretion and eosinophil survival (2006) (39)
Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain (2013) (38)
The Loss of Smell in Persistent Allergic Rhinitis Is Improved by Levocetirizine due to Reduction of Nasal Inflammation but Not Nasal Congestion (the CIRANO Study) (2012) (38)
Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease. (2016) (38)
Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review (2012) (38)
CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report (2017) (38)
Position paper on nasal obstruction: evaluation and treatment. (2018) (38)
Allergic conjunctivitis and H1 antihistamines. (2009) (37)
The sense of smell in chronic rhinosinusitis. (2020) (37)
Mobile technology in allergic rhinitis: evolution in management or revolution in health and care? (2019) (36)
Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. (2010) (36)
The impact of bronchiectasis associated to sinonasal disease on quality of life. (2006) (36)
The Impact of Atopy, Sinus Opacification, and Nasal Patency on Quality of Life in Patients with Severe Nasal Polyposis (2006) (36)
Glucocorticoid receptor isoforms alpha and beta in in vitro cytokine-induced glucocorticoid insensitivity. (2004) (35)
Endothelin-1 stimulates eicosanoid production in cultured human nasal mucosa. (1992) (35)
M1 and M3 muscarinic antagonists inhibit human nasal glandular secretion in vitro. (1992) (35)
Interactions of the H1 antihistamines. (2006) (34)
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice (2020) (34)
ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy” (2019) (34)
Corticosteroid therapy increases membrane‐tethered while decreases secreted mucin expression in nasal polyps (2008) (34)
Oral and intranasal steroid treatments improve nasal patency and paradoxically increase nasal nitric oxide in patients with severe nasal polyposis. (2012) (34)
Aspirin Desensitization: Useful Treatment for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Aspirin-Exacerbated Respiratory Disease (AERD)? (2014) (34)
The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. (2017) (34)
Endothelial L‐selectin ligand expression in nasal polyps (2010) (33)
Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo-controlled trial. (2012) (33)
Muscarinic receptor subtypes in human nasal mucosa: characterization, autoradiographic localization, and function in vitro. (1993) (32)
Effect of budesonide and nedocromil sodium on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells. (2001) (32)
Clinical use of oral antihistamines and intranasal corticosteroids in patients with allergic rhinitis. (2011) (32)
Long-term outcomes of endoscopic endonasal approach for skull base surgery: a prospective study (2016) (32)
Nasal manifestations of systemic illnesses (2004) (32)
Epidemiologic, clinical and socioeconomic factors of atopic dermatitis in Spain: Alergológica-2005. (2009) (31)
Effect of H1 antihistamines upon the central nervous system. (2006) (31)
Peripheral primitive neuroectodermal tumour of the left maxillary sinus (2003) (31)
Use of a monoclonal antibody enzyme-linked immunosorbent assay to measure human respiratory glycoprotein production in vitro. (1991) (31)
Effect of H1 antihistamines upon the cardiovascular system. (2006) (31)
Olfactory Training in Post-Traumatic Smell Impairment: Mild Improvement in Threshold Performances: Results from a Randomized Controlled Trial. (2018) (31)
Allergic rhinitis: continuous or on demand antihistamine therapy? (2007) (31)
The importance of smell in patients with bronchiectasis. (2011) (31)
Importance of glucocorticoid receptors in upper and lower airways. (2010) (30)
Current controversies and challenges in allergic rhinitis management (2015) (30)
Dupilumab improves upper- and lower-airway disease control in chronic rhinosinusitis with nasal polyps and asthma. (2021) (30)
Impact of Sleep as a Specific Marker of Quality of Life in Allergic Rhinitis (2013) (30)
Nasal obstructive disorders impair health‐related quality of life in adolescents with persistent allergic rhinitis: A real‐life study (2017) (30)
Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study (2018) (29)
Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA2LEN consensus (2021) (29)
Nitric Oxide: A Promising Methodological Approach in Airway Diseases (2011) (29)
The effects of neuropeptides on mucous glycoprotein secretion from human nasal mucosa in vitro (1992) (29)
The impact of allergic rhinitis on symptoms, and quality of life using the new criterion of ARIA severity classification. (2012) (29)
Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study (2018) (29)
Rhinitis Phenotypes. (2020) (28)
Response of the nose to exercise in healthy subjects and in patients with rhinitis and asthma. (1994) (28)
Effect of antihistamine up-dosing in chronic urticaria. (2011) (27)
Nasal and bronchial inflammation after nasal allergen challenge: assessment using noninvasive methods. (2012) (27)
Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA (2020) (27)
Glucocorticoid Receptor in Human Respiratory Epithelial Cells (2009) (27)
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. (2019) (27)
Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe. (2017) (27)
Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study (2020) (26)
Controversies in the treatment of chronic rhinosinusitis (2010) (26)
Corticosteroid treatment regulates mucosal remodeling in chronic rhinosinusitis with nasal polyps (2015) (26)
Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases (2020) (25)
Low prostaglandin E2 and cyclooxygenase expression in nasal mucosa fibroblasts of aspirin‐intolerant asthmatics (2013) (25)
Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19 (2021) (25)
Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study (2016) (25)
Management of Chronic Rhinosinusitis in Asthma Patients: Is There Still a Debate? (2014) (25)
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. (2012) (25)
Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis. (2011) (25)
In vitro release of arachidonic acid metabolites, glutathione peroxidase, and oxygen-free radicals from platelets of asthmatic patients with and without aspirin intolerance. (1995) (25)
Discrimination between moderate and severe disease may be used in patients with either treated or untreated allergic rhinitis (2010) (24)
Allergy rhinitis: similarities and differences between children and adults. (2017) (24)
ARIA guideline 2019: treatment of allergic rhinitis in the German health system. (2019) (24)
Expression of glucocorticoid receptors alpha and beta in steroid sensitive and steroid insensitive interstitial lung diseases. (2004) (24)
Inhibition of GM-CSF secretion by topical corticosteroids and nedocromil sodium. A comparison study using nasal polyp epithelial cells. (2000) (24)
Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications (2019) (23)
A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress (2015) (23)
Does rhinitis lead to asthma? (2007) (23)
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK‐air® App (2020) (23)
Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine (2005) (23)
Reconstituted Human Upper Airway Epithelium as 3-D In Vitro Model for Nasal Polyposis (2014) (23)
Smell and Taste Dysfunction in COVID-19 Is Associated With Younger Age in Ambulatory Settings: A Multicenter Cross-Sectional Study (2020) (22)
Smell training increases cognitive smell skills of wine tasters compared to the general healthy population. The WINECAT Study. (2010) (22)
MicroRNA in United Airway Diseases (2016) (22)
Differential Expression of Remodeling Markers by Tissue Structure in Nasal Polyposis (2013) (22)
Common Cold and Acute Rhinosinusitis: Up-to-Date Management in 2020 (2020) (22)
SEAIC-SEORL. Consensus Document on Nasal Polyposis. POLINA Project. (2011) (22)
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. (2010) (22)
Bilastine and the central nervous system. (2011) (22)
Increased cardiovascular and anxiety outcomes but not endocrine biomarkers of stress during performance of endoscopic sinus surgery: a pilot study among novice surgeons. (2011) (21)
Nasal and bronchial response to exercise in patients with asthma and rhinitis: the role of nitric oxide (2005) (21)
Antileukotrienes improve naso‐ocular symptoms and biomarkers in patients with NARES and asthma (2018) (21)
Immunocytologic analysis of nasal cells obtained by nasal lavage: a comparative study with a standard method of cell identification (1993) (21)
Clinical and Biological Markers of Difficult-to-Treat Severe Chronic Rhinosinusitis (2015) (21)
A Randomized Phase 3 Study, Sinus‐52, Evaluating the Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps: L36 (2019) (20)
The optimal evaluation and management of patients with a gradual onset of olfactory loss (2014) (20)
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies (2016) (20)
Regulation of ICAM‐3 and other adhesion molecule expressions on eosinophils in vitro. Effects of dexamethasone (1999) (20)
Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells (2011) (19)
Combined Oral and Intranasal Corticosteroid Therapy: An Advance in the Management of Nasal Polyposis? (2011) (19)
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. (2021) (19)
Multiple chemical sensitivity worsens quality of life and cognitive and sensorial features of sense of smell (2014) (19)
Specialist‐based treatment reduces the severity of allergic rhinitis (2013) (19)
Reference values for facilitating the interpretation of the ESPRINT-15 questionnaire (Spanish version). (2009) (19)
Proinflammatory cytokines and eosinophil cationic protein on glandular secretion from human nasal mucosa: regulation by corticosteroids. (2001) (19)
Vasoactive intestinal peptide (VIP) induces IL-6 and IL-8, but not G-CSF and GM-CSF release from a human bronchial epithelial cell line (1997) (19)
Lack of long‐term add‐on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps (2018) (18)
Loss of smell but not taste in adult women with Turner's syndrome and other congenital hypogonadisms. (2012) (18)
Rupatadine: global safety evaluation in allergic rhinitis and urticaria (2016) (18)
Effects of topical glucocorticoids on in vitro lactoferrin glandular secretion: comparison between human upper and lower airways. (2000) (18)
Integrated mRNA and microRNA transcriptome profiling during differentiation of human nasal polyp epithelium reveals an altered ciliogenesis (2020) (17)
Proteasome Inhibition Reduces Proliferation, Collagen Expression, and Inflammatory Cytokine Production in Nasal Mucosa and Polyp Fibroblasts (2012) (17)
Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design (2013) (17)
Development and validation of combined symptom‐medication scores for allergic rhinitis * (2021) (17)
Platelet-activating Factor Nasal Challenge Induces Nasal Congestion and Reduces Nasal Volume in Both Healthy Volunteers and Allergic Rhinitis Patients (2013) (17)
Use of second generation H1 antihistamines in special situations. (2013) (17)
Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts (2009) (16)
Effect of pollutants upon patients with respiratory allergies. (2007) (16)
Multimorbidities of Pediatric Allergic Rhinitis (2019) (16)
[Relation between rhinosinusitis and bronchiectasis]. (2006) (16)
Spices to Control COVID-19 Symptoms: Yes, but Not Only… (2020) (16)
Rupatadine improves nasal symptoms, quality of life (ESPRINT-15) and severity in a subanalysis of a cohort of Spanish allergic rhinitis patients. (2011) (16)
Influence of nasal septum deformity on nasal obstruction, disease severity, and medical treatment response among children and adolescents with persistent allergic rhinitis. (2017) (16)
Accuracy of acoustic rhinometry versus computed tomography in the evaluation of nasal cavity in patients with nasal polyposis. (2010) (15)
Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review (2020) (15)
Olfactory Training Prevents Olfactory Dysfunction Induced by Bulbar Excitotoxic Lesions: Role of Neurogenesis and Dopaminergic Interneurons (2019) (15)
ESPRINT-15 questionnaire (Spanish version): reference values according to disease severity using both the original and the modified ARIA classifications. (2013) (15)
Bilastine and quality of life. (2011) (15)
Nasal obstructive disorders induce medical treatment failure in paediatric persistent allergic rhinitis (The NODPAR Study) (2017) (15)
A possible role of stem cells in nasal polyposis (2017) (15)
[Cyclooxigenase-2 levels are increased in the lung tissue and bronchial tumors of patients with chronic obstructive pulmonary disease]. (2011) (14)
Altered expression and signalling of EP2 receptor in nasal polyps of AERD patients: role in inflammation and remodelling. (2017) (14)
Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis (2008) (14)
Hearing loss in adult women with Turner’s syndrome and other congenital hypogonadisms (2014) (14)
Recovery of Olfactory Function After Excitotoxic Lesion of the Olfactory Bulbs Is Associated with Increases in Bulbar SIRT1 and SIRT4 Expressions (2019) (14)
Mucin gene expression in rhinitis syndromes (2006) (14)
Safety evaluation of desloratadine in allergic rhinitis (2013) (14)
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials (2021) (14)
Olfactory function in an excitotoxic model for secondary neuronal degeneration: Role of dopaminergic interneurons (2017) (14)
Smell loss is associated with severe and uncontrolled disease in children and adolescents with persistent allergic rhinitis. (2018) (14)
Trends on rhinosinusitis diagnosis and treatment. (2009) (13)
Release of chemical mediators and inflammatory cell influx during early allergic reaction in the nose: effect of furosemide. (1993) (13)
Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study. (2009) (13)
Effects of nedocromil sodium on allergen-induced rhinitis in humans. (1992) (13)
Comparative pharmacology of the H 1 antihistamines (2006) (13)
[ARIA (Allergic Rhinitis and its Impact on Asthma) achievements in 10 years and future needs]. (2012) (13)
Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps. (2021) (13)
Pharmacoeconomics of Cyclamen europaeum in the management of acute rhinosinusitis (2013) (13)
Cell content and albumin concentration in nasal lavage from patients with rhinitis. (1993) (13)
Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK‐air® (2021) (13)
Bilastine for the treatment of urticaria (2013) (12)
Psychophysical olfactory testing in COVID‐19: is smell function really impaired in nearly all patients? (2020) (12)
Chronic Rhinosinusitis and COVID-19 (2022) (12)
Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis (2016) (12)
Role of microRNAs in inflammatory upper airway diseases (2020) (12)
La ciclooxigenasa-2 está regulada al alza en el pulmón y en los tumores bronquiales de pacientes con enfermedad pulmonar obstructiva crónica (2011) (12)
Olfaction in patients with allergic rhinitis: an indicator of successful MP‐AzeFlu therapy (2017) (12)
Glucocorticoid therapy increases COX-2 gene expression in nasal polyps in vivo (2009) (12)
Lower sensitivity of nasal polyp fibroblasts to glucocorticoid anti-proliferative effects. (2011) (12)
Olfactory Dysfunction in Traumatic Brain Injury: the Role of Neurogenesis (2020) (11)
Signal Transduction Pathways (MAPKs, NF-κB, and C/EBP) Regulating COX-2 Expression in Nasal Fibroblasts from Asthma Patients with Aspirin Intolerance (2012) (11)
Effect of bilastine upon nasal obstruction. (2011) (11)
CIRUGÍA ENDOSCÓPICA NASOSINUSAL EN LA SINUSITIS FÚNGICA. NUESTRA EXPERIENCIA (2002) (11)
Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers (2018) (11)
Management of anaphylaxis due to COVID‐19 vaccines in the elderly (2021) (11)
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (10)
ACE2 downregulation in olfactory mucosa: Eosinophilic rhinosinusitis as COVID‐19 protective factor? (2021) (10)
The effect of IL-4 on human nasal mucosal responses. (1992) (10)
Prevalence and characteristics of rhinitis in asthmatic patients attending primary care in Spain (the RINOASMAIR study). (2010) (10)
Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). (2017) (10)
Orbitoethmoid aneurysmal bone cyst. Case report and literature review. (2004) (10)
THE NOSE IN ASPIRIN-SENSITIVE ASTHMA (1998) (10)
Effect of Lipopolysaccharide on Glucocorticoid Receptor Function in Control Nasal Mucosa Fibroblasts and in Fibroblasts from Patients with Chronic Rhinosinusitis with Nasal Polyps and Asthma (2015) (10)
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (10)
ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy (2021) (10)
The impact of chronic rhinosinusitis and nasal polyposis in quality of life. (2009) (9)
Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2). (2019) (9)
The MEGA Project: A Study of the Mechanisms Involved in the Genesis and Disease Course of Asthma. Asthma Cohort Creation and Long-Term Follow-Up. (2018) (9)
Chemosensory Dysfunction in Patients with COVID-19: What Do We Learn from the Global Outbreak? (2021) (9)
Antileukotrienes in rhinosinusitis and nasal polyposis (2008) (9)
Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1). (2019) (9)
Measuring outcomes in allergic rhinitis: psychometric characteristics of a Spanish version of the congestion quantifier seven-item test (CQ7) (2011) (9)
Parapharyngeal angiolipoma causing obstructive sleep apnoea syndrome (2004) (9)
Paediatric Barcelona Olfactory Test-6 (pBOT-6): Validation of a Combined Odour Identification and Threshold Screening Test in Healthy Spanish Children and Adolescents. (2019) (8)
[Eosinophil activation by epithelial cells of the respiratory mucosa. Comparative study of normal mucosa and inflammatory mucosa]. (1997) (8)
Chronic Rhinosinusitis with Nasal Polyps: Quality of Life in the Biologics Era. (2022) (8)
Transoral approach to drain streptococcus pneumoniae spinal epidural abscess in an HIV-infected adult (2004) (8)
Deficient glucocorticoid induction of anti-inflammatory genes in nasal polyp fibroblasts of asthmatic patients with and without aspirin intolerance. (2013) (8)
Lack of additive benefit of oral steroids on short‐term postoperative outcomes in nasal polyposis (2019) (8)
Adaptation to Spanish and validation of the Rhinitis Control Assessment Test (RCAT) questionnaire. (2020) (8)
Functional Examination of the Upper and Lower Airways in Asthma and Respiratory Allergic Diseases: Considerations in the Post–SARS-CoV-2 Era (2021) (7)
Striatal and nigral COX-2 expression after chronic typical and atypical neuroleptic administration in rats (2007) (7)
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper (2021) (7)
Upper and Lower Airways Functional Examination in Asthma and Respiratory Allergic Deseases. Considerations in the SARS-CoV-2 Post-Pandemic Situation. (2020) (7)
Clinical-Pathological Correlation of the Pathophysiology and Mechanism of Action of COVID-19 — a Primer for Clinicians (2021) (7)
D450 OMALIZUMAB EFFICACY AND SAFETY IN NASAL POLYPOSIS: RESULTS FROM TWO PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (2019) (7)
Failure of frusemide to increase production of prostaglandin E2 in human nasal mucosa in vivo. (1993) (7)
Prevalencia y características de la rinitis en pacientes asmáticos de las consultas de Atención Primaria, Alergología y Neumología en España (Estudio AIR) (2011) (7)
Endothelin and the airway mucosa. (1998) (7)
Fluticasone Furoate Inhibits Cytokine Secretion from Nasal Epithelial Cells and Reduces Eosinophil Survival in an in vitro Model of Eosinophilic Inflammation (2014) (7)
Olfaction in LRRK2 Linked Parkinson's Disease: Is It Different from Idiopathic Parkinson's Disease? (2020) (7)
Topical glucocorticoids downregulate COX‐1 positive cells in nasal polyps (2009) (7)
Clinical and inflammatory characteristics of patients with asthma in the Spanish MEGA project cohort (2021) (7)
Extranodal Lymphoma Originating from Mucosa-associated Lymphoid Tissue of the Nasopharynx (2003) (7)
Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma (2020) (7)
Should postviral anosmia be further investigated? (2009) (7)
Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis (2019) (6)
Mecanismos de acción de los glucocortícoides. Aplicación al tratamiento de la inflamación respiratoria (1996) (6)
Alteraciones olfativas en las rinitis alérgicas a pólenes y ácaros (2008) (6)
Self-perception of olfactory dysfunction is associated with history of Traumatic Brain Injury: post-hoc analysis from the OLFACAT survey. (2019) (6)
Antihistamines in drivers, aircrew and occupations of risk. (2013) (6)
Innovative Surgical Techniques for Nasal Septal Perforations: Management and Treatment (2021) (6)
Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms (2020) (6)
Prodromal Parkinson disease in patients with idiopathic hyposmia (2020) (6)
Rhinitis of granulomatous and vasculitic diseases. (2007) (6)
Chronic rhinosinusitis with and without nasal polyps and rhinitis in adult asthma. Frequency distribution and relationship with asthma control and severity (the IRIS-ASMA study) (2013) (6)
Management of United Airway Disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. (2022) (5)
Translocación nuclear del receptor de glucocorticoides en fibroblastos de pacientes asmáticos con poliposis nasal insensible al tratamiento glucocorticoideo (2011) (5)
Validation of the MASK‐air app for assessment of allergic rhinitis (2020) (5)
Quality of life measures in patients on rhinosinusitis trials (2013) (5)
Multidisciplinary Care for Severe or Uncontrolled Chronic Upper Airway Diseases (2021) (5)
Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK‐air® real‐world data (2022) (5)
Churg-Strauss Syndrome or Eosinophilic Granulomatosis with Polyangiitis (2015) (5)
ARIA update 2008: allergic rhinitis and its effect on asthma (2009) (5)
The MEGA Project: A Study of the Mechanisms Involved in the Genesis and Disease Course of Asthma. Asthma Cohort Creation and Long-Term Follow-Up (2018) (5)
H1 antihistamines and benzodiazepines. Pharmacological interactions and their impact on cerebral function. (2013) (5)
Effects on nasal nitric oxide production of 2 mechanisms of vasoconstriction. (2007) (5)
ARIA masterclass 2018: From guidelines to real-life implementation. (2019) (5)
Cyclamen europaeum improves the effect of oral antibiotics on exacerbations and recurrences of chronic rhinosinusitis: a real-life observational study (CHRONOS). (2018) (5)
Correction to: Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper (2020) (5)
Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial (2017) (5)
D202 CONTINUED SAFETY/EFFICACY OF OMALIZUMAB IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: AN OPEN-LABEL EXTENSION STUDY (2020) (5)
[Prevalence and characteristics of rhinitis in adult asthmatic patients attending allergist, primary care and pulmonologist settings in Spain (AIR study)]. (2011) (5)
P167: Epidemiologic Study of Smell in the Catalan Population (2006) (5)
Management of Rhinosinusitis Today (2008) (5)
Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model (2022) (4)
Validation of the ARIA items to assess allergic rhinitis control (ARIA‐C) (2020) (4)
Eicosanoid dysregulation and type 2 inflammation in AERD. (2021) (4)
Nuclear factor kappa‐B p50 and p65 subunits expression in dementia with Lewy bodies (2007) (4)
Atopic Comorbidities and Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Who Failed Intranasal Corticosteroids (2018) (4)
MASK (Mobile Airways Sentinel Network). La solución integral de ARIA por app móvil para la multimorbilidad de rinitis alérgica y asma (2019) (4)
MicroRNA: Endotyping United Airways? (2014) (4)
4th Pediatric Allergy and Asthma Meeting (PAAM) (2016) (4)
Estudio de los mecanismos implicados en la génesis y evolución del asma (proyecto MEGA): creación y seguimiento a largo plazo de una cohorte de pacientes asmáticos (2018) (4)
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (2017) (4)
Long-Term Treatment of Persistent Allergic Rhinitis with Levocetirizine (2007) (4)
[Sino-nasal endoscopic surgery in fungal sinusitis. Our experience]. (2002) (4)
Editorial: The nose – from symptoms to evidence‐based medicine (2007) (4)
Olfactory Dysfunction in a Mexican Population Outside of COVID-19 Pandemic: Prevalence and Associated Factors (the OLFAMEX Study) (2020) (4)
Impact of cell culture methods on the outcomes of the in vitro inflammatory response in nasal polyps. (2011) (4)
309 Endothelin in human nasal mucosa (1991) (4)
Differences in Inflammatory Cytokine Profile in Obesity-Associated Asthma: Effects of Weight Loss (2022) (4)
Interactions of the H 1 antihistamines (2006) (4)
[MASK (Mobile Airways Sentinel Network). ARIA's comprehensive solution for mobile app for the multimorbidity of allergic rhinitis and asthma]. (2019) (4)
The ‘GA²LEN Sinusitis Cohort’: an introduction (2015) (4)
Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact (2023) (3)
Epidemiology of Allergic Rhinitis (2019) (3)
Predictive factors for invasive fungal rhinosinusitis in diabetic patients: Systematic review and data re-analysis. (2020) (3)
Omalizumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps Irrespective of Asthma Status (2020) (3)
Exacerbations among patients with asthma are largely dependent on the presence of multimorbidity. (2022) (3)
Nasal polyps, aspirin sensitivity, and late onset asthma are crucial to identify severe asthma. clinicaltrials.gov id : nct01513837 (2015) (3)
Academic productivity of young people with allergic rhinitis: A MASK-air® study. (2022) (3)
Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). (2017) (3)
A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch (2015) (3)
A new allergic rhinitis therapy (MP29-02) is more effective than current first line monotherapies in providing allergic rhinitis patients relief from their nasal and ocular symptoms (rTNSS, rT5SS, rT7SS) (2013) (3)
Assessment of craniofacial hyperhidrosis and flushing by sphenopalatine blockade - a randomized trial. (2019) (3)
Pediatric Barcelona Olfactory Test ̶ 6 ( pBOT-6 ) : Validation of a Combined Odor Identification and Threshold Screening Test in Healthy Spanish Children and Adolescents (2020) (3)
MP29-02* reduces eosinophil survival induced by epithelial cell secretions from nasal mucosa (2015) (3)
Amphotericin B nasal lavages: not a solution for patients suffering from chronic rhinosinusitis. (2006) (3)
Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis. (2020) (3)
Immune response to fungi in diabetic patients with invasive fungal rhinosinusitis. (2020) (3)
Aspirin Sensitivity as a Clinical Marker for Severe Asthma and United Airway Disease (2014) (3)
Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis (2020) (3)
Peripheral primitive neuroectodermal tumor of the cerebellopontine angle (2005) (3)
Impact of Nasal Polyposis and Its Medical or Surgical Treatment on Quality of Life (2004) (3)
Olfactory dysfunction during COVID-19 pandemic. (2020) (3)
Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps. (2022) (3)
Comparison of rhinitis treatments using MASK‐air® data and considering the minimal important difference (2022) (3)
antihistamines : psychomotor performance and driving H 1 antihistamines : psychomotor performance and driving (3)
Recovery of Olfactory Function After Excitotoxic Lesion of the Olfactory Bulbs Is Associated with Increases in Bulbar SIRT1 and SIRT4 Expressions (2019) (2)
[Sphenochoanal polyp. Diagnostic and therapeutic aspects]. (2006) (2)
The ARIA approach of Value-Added Medicines: as-needed treatment in allergic rhinitis. (2022) (2)
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies (2022) (2)
Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA (2016) (2)
Asthma with nasal polyps: The “severe” phenotype? ClinicalTrials.gov ID: NCT01513837 (2014) (2)
Current evaluation and management of patients with chronic rhinosinusitis and nasal polyps (2022) (2)
Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial (2017) (2)
Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities (2022) (2)
Admixture mapping of severe asthma exacerbations in Hispanic/Latino children and youth (2022) (2)
Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial (2016) (2)
Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials (2019) (2)
Nuclear translocation of the glucocorticoid receptor in fibroblasts of asthmatic patients with nasal polyposis insensitive to glucocorticoid treatment. (2011) (2)
Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab (2021) (2)
Presentation of airway and general symptoms in COVID‐19 caused by dominant SARS‐CoV‐2 variants: A follow‐up on ARIA consensus (2022) (2)
The Debate: Regular Versus As-Needed Use of Intranasal Corticosteroids for a Patient-Centered Approach. (2021) (2)
Errors and Biases in Meta-analysis of the Prevalence of Olfactory Dysfunction in Patients With COVID-19 (2020) (2)
Olfactory dysfunction during COVID-19 pandemic☆ (2020) (2)
Efectos de la deficiencia visual sobre la función olfativa (2010) (2)
Pérdida del sentido del olfato durante la pandemia COVID-19 (2020) (2)
Influence of the diagnosis chronic rhinosinusitis on asthma response to omalizumab in severe, uncontrolled asthmatics (2015) (2)
Prevalence of Atopy to Common Aeroallergens and Moulds in Patients with Nasal Polyposis (2004) (2)
Direct costs of Acute Rhinosinusitis in Spain - a prospective and observational study (PROSINUS). (2020) (2)
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In‐depth sinus surgery analysis (2022) (2)
[Olfactory alterations in allergic rhinitis to pollens and mites]. (2008) (2)
BASICS OF MUSCARINIC PHYSIOLOGY (1999) (2)
MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis (2020) (2)
Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK‐air® longitudinal study (2022) (2)
A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity. (2015) (2)
Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials (2019) (2)
Asthma-Related Outcomes in A Real-World Study of MP-AzeFlu to Treat Allergic Rhinitis (2020) (1)
Loss of smell: a clinical marker of severe asthma (2018) (1)
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023 (2023) (1)
Omalizumab Improves Quality of Life in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma (2020) (1)
IgE plasma level in asthmatics with nasal polyps is independent of atopy (2016) (1)
CHronic RhINOSinusitis Outcome Registry (CHRINOSOR): establishment of an international outcome registry driven by mHealth technology. (2022) (1)
Anxiety and BMI affect asthma control: data from a prospective Spanish cohort. (2021) (1)
High frequency of smell and taste dysfunctions in allergy health care professionals suffering from COVID-19. (2021) (1)
Truths and fakes in the smell terminology during the COVID‐19 outbreak (2021) (1)
Clivus Rathke cleft cyst: case report of a rare disease and literature review (2018) (1)
Cyclamen europaeum improves the effect of oral antibiotics on exacerbations and recurrences of chronic rhinosinusitis: a real-life observational study (CHRONOS). (2018) (1)
Efficacy of Desloratadine in Persistent Allergic Rhinitis -- A GAtextsuperscript2LEN Study (2010) (1)
Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study. (2021) (1)
Validation of the DECA criteria for allergic conjunctivitis severity and control (2020) (1)
Reply. (2020) (1)
Reference Gene Validation for RT–qPCR in PBMCs from Asthmatic Patients with or without Obesity (2022) (1)
Observational study evaluating nighttime and early morning treatment satisfaction in patients receiving once daily desloratadine for seasonal allergic rhinitis in routine daily practice in Saudi Arabia (2008) (1)
Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air® approach (2023) (1)
[Mechanisms of action of glucocorticoids. Application to the treatment of respiratory inflammation]. (1996) (1)
Correction to “ARIA guideline 2019: treatment of allergic rhinitis in the German health system” (2020) (1)
Nuclear Translocation of the Glucocorticoid Receptor in Fibroblasts of Asthmatic Patients with Nasal Polyposis Insensitive to Glucocorticoid Treatment (2011) (1)
Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease (2020) (1)
Loss of smell in patients with traumatic brain injury is associated with neuropsychiatric behavioral alterations (2021) (1)
Dupilumab Treatment Improves Sense of Smell in Patients With Chronic Rhinosinusitis With Nasal Polyps – Pooled Results From the SINUS-24 and SINUS-52 Phase 3 Trials (2020) (1)
MP29-02* provides a rapid clinically-meaningful response for moderate/severe seasonal allergic rhinitis patients : a meta-analysis (2015) (1)
Erratum to: Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (2017) (1)
A Decade of Clinical Advances in Chronic Rhinosinusitis: 2012-2022. (2023) (1)
Olfactory Bulb Excitotoxicity as a Gap-Filling Mechanism Underlying the Link Between Traumatic Brain Injury-Induced Secondary Neuronal Degeneration and Parkinson’s Disease-Like Pathology (2022) (1)
Development of an international odor identification test for children – the “U-Sniff” test (2018) (1)
Pólipo esfenocoanal: aspectos diagnósticos y terapéuticos (2006) (1)
Neuropéptidos. Su papel en la fisiopatología respiratoria humana (1993) (1)
Weight loss and vitamin D improve hyporesponsiveness to corticosteroids in obese asthma. (2022) (1)
Rinitis y asma (2005) (1)
Update about Oralair® as a treatment for grass pollen allergic rhinitis (2022) (1)
1,25-dihydroxyvitamin D3 effect on corticosteroid sensitivity in obese asthmatic patients before and after bariatric surgery (2020) (0)
Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study (2020) (0)
Radiology quiz case 1. Diagnosis: Right antrochoanal polyp (ACP). (2005) (0)
The 8-Odorant Barcelona Olfactory Test (BOT-8): Validation of a New Test in the Spanish Population During the COVID-19 Pandemic (2022) (0)
GA(2)LEN sinusitis cohort study: chronic rhinosinusitis -differentiation based on chemokine pattern and IL-5 (2012) (0)
132 Characterization of 2 Epithelial Cell Air-Liquid Interface (ALI) Culture Models for Human Healthy Nasal Mucosa and Nasal Polyps (2012) (0)
High Frequency of Smell and Taste Dysfunction in Health Care Professionals With COVID-19 Working in Allergy Departments. (2021) (0)
Management of allergic rhinitis symptoms in the pharmacy Pocket guide 2022 (2022) (0)
Improvement of daily allergy control by sublingual immunotherapy: A MASK-air® study. (2023) (0)
Nonallergic Rhinitis and Primary Ciliary Dyskinesia (2010) (0)
Baseline characteristics of phase 3 randomized controlled trials of omalizumab in chronic rhinosinusitis with nasal polyps (2019) (0)
The GALEN sinusitis cohort : impact on quality of life in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (2015) (0)
EL21 European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2012 (2012) (0)
on eosinophil survival primed bycultured epithelial cell supernatants obtained fromnasal mucosa andnasal polyps (2011) (0)
Barcelona Olfactory Test - 8: validation of a new test on Spanish population during COVID-19 pandemic. (2022) (0)
yclooxigenase-2 Levels Are Increased in the Lung Tissue and Bronchial Tumors f Patients With Chronic Obstructive Pulmonary Disease (2018) (0)
Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: A hypothesis. (2022) (0)
Endothelin and the Airway Epithelium (1999) (0)
Effect of MP-AzeFlu in IL-1 beta-induced IL-6 and proinflammatory cytokines. (2022) (0)
International Symposia: Basic Research: Attractive Training for a New Generation of Otorhinolaryngologists (2003) (0)
Evaluation of second generation antihistamines following a 2 or 4-weeks treatment by means of a pooled responder analysis in patients suffering from seasonal allergic rhinitis (2008) (0)
Abstract64 Effects of nedocrumil sodium on allergen-induced rhinitis in humans (1991) (0)
Treatment of allergic rhinitis using mobile technology with real world data (2018) (0)
Effect of MP‐AzeFlu compared to monotherapy on COX‐2, PGE2, and EP2 gene expression in upper airway mucosa (2022) (0)
Is More and Longer Better? Long-Term and High-Dose Glucocorticosteroids (2014) (0)
Glucocorticoids downregulate COX-1 positive cells in nasal polyps (2005) (0)
Failure offrusemide toincrease production of prostaglandin E2inhumannasal mucosainvivo (1993) (0)
Original article Efficacy and safety of bilastine 20mg compared with cetirizine 10mg and placebo in the treatment of perennial allergic rhinitis (2012) (0)
Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study (2023) (0)
Subject Index Vol. 153, 2010 (2010) (0)
demodulationcytometry with frequency domain Measurement of cell microrheology by magnetic (2015) (0)
3 . 2 Lack of efficacy of long-term low-dose azithromycin in chronic rhinosinusitis : a randomized controlled trial (2011) (0)
Loss of Smell in Allergic Rhinitis and Related Disorders (2020) (0)
COVID-19 as a turning point in the need for specialized units for the sense of smell. (2023) (0)
Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis (2023) (0)
Mometasone and Desloratadine Have an Additive Effect on Eosinophil Survival Induced by Epithelial Cells Culture Supernatants from Nasal Mucosa and Polyps (2008) (0)
Asthma and severe obesity: glucocorticoid sensitivity before and after bariatric surgery (2019) (0)
Endoscopic Repair of Anterior Skull Base Defects (2010) (0)
Pheno-Endotyping Antrochoanal Nasal Polyposis (2023) (0)
Severe nasal polyposis and its impact on sinus opacification (2006) (0)
Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial (2020) (0)
Response ofthenosetoexercise inhealthy subjects andinpatients withrhinitis andasthma (1994) (0)
European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis (2023) (0)
European view on the pathology of chronic rhinosinusitis, nasal polyposis and the impact of staphylococcal enterotoxins: first results of the Ga2len sinusitis cohort study (2011) (0)
Evaluation of Nasal Patency and Nasal Nitric Oxide Levels in Subjects with Allergic Rhinitis After Pharmacologic or Physiologic Stimuli: a Two Parallel Groups Study (2006) (0)
Nasal secretion assays predict superantigen involvement in nasal polyposis (2011) (0)
Cigarette smoking is decresed in severe asthma and associated with chronic rhinosinusitis without nasal polyps (2019) (0)
Patología de la vía respiratoria superior en el asma. Tratamiento con Reslizumab. (2018) (0)
Cut-off values of MASK-air® Patient-Reported Outcome Measures (PROMs). (2022) (0)
Platelet activating factor-induced mast cell degranulation is inhibited by rupatadine, and to a lower extent by levocetirizine and desoratadine, in a mast cell line (LAD-2) (2013) (0)
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials (2021) (0)
Scientific flash July 2013 Pharmacoeconomics of Cyclamen europaeum ( Nasodren ® / Sinuforte ® ) in the management of Acute Rhinosinusitis (2008) (0)
Immunopathology of Nasal Polypi (2004) (0)
Baseline Characteristics of Patients With Chronic Rhinosinusitis With Nasal Polyps (With and Without Asthma) Enrolled in SINUS-52, a Randomized, Double-Blind, Phase 3 Study of Dupilumab (2019) (0)
Superior effect of MP‐AzeFlu compared to monotherapy with fluticasone propionate or azelastine on GILZ, MKP‐1 and TTP anti‐inflammatory gene expression in healthy and inflamed upper airway mucosa (2022) (0)
Prevalence of Atopic Dermatitis in the adult population of Catalonia (Spain): a retrospective, large-scale population-based study. (2023) (0)
Mepolizumab treatment for severe eosinophilic asthma: a 5-years real-life experience. (2023) (0)
Fluticasone Furoate Decreases Nasal Eosinophilic Inflammation by Inhibiting Both Cytokine Secretion From Nasal Mucosa Epithelial Cells Cytokine Secretion and Eosinophil Survival (2013) (0)
Higher evidence for specific immunotherapy than reported in the ARIA update. (2008) (0)
Characterization of two epithelial cell air-liquid interface (ALI) culture models for human healthy nasal mucosa and nasal polyps (2013) (0)
Abstracts from the 11th Symposium on Experimental Rhinology and Immunology of the Nose (SERIN 2017) (2017) (0)
Nasal Congestion and Headache (2019) (0)
[On the translation of lobar and lobectomy into Spanish]. (2005) (0)
Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis. (2023) (0)
Reply (2020) (0)
Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps (2022) (0)
[MASK (Mobile Airways Sentinel Network), a mobile App with ARIA's comprehensive solution in Spanish-speaking countries]. (2019) (0)
10 Nonallergic Rhinitis and Primary Ciliary Dyskinesia (0)
Accuracy of Acoustic Rhinometry Versus Computed Tomography in the Evaluation of Nasal Cavity in Patients with Nasal Polyposis (2008) (0)
Nasal Congestion Worsens Sleep Disturbance and Psychological Wellness in Allergic Rhinitis Patients (2013) (0)
Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma from the Pooled Populations of the SINUS-24 and SINUS-52 Dupilumab Phase 3 Trials (2020) (0)
Patient-centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA-EAACI approach. (2023) (0)
Annoying Nasal Itching and Rhinorrhea (2019) (0)
COX-1 AND COX-2 ARE UP-REGULATED IN NASAL POLYPS IN CYSTIC FIBROSIS (2006) (0)
[Executive Summary of ARIA 2019: Integrated care pathways for allergic rhinitis in Argentina, Spain and Mexico]. (2019) (0)
Allergic rhinitis: similarities and differences between children and adults* (2017) (0)
Chronic Rhinosinusitis: Forward! (2022) (0)
Lipopolysacharide modulates glucocorticoid receptor function in nasal mucosa and polyp fibroblasts (2013) (0)
Contents Vol. 153, 2010 (2010) (0)
How reliably can algorithms identify eosinophilic asthma phenotypes using non‐invasive biomarkers? (2022) (0)
Desloratadine inhibits GM-CSF secretion from nasal mucosa and polyps and eosinophil survival induced by epithelial cells (2004) (0)
Current controversies and challenges in allergic rhinitis (2015) (0)
Nonallergic Rhinitis-Identifying Gaps in Research (2011) (0)
551 The Impact of Nasal Polyposis on Quality of Life Using the Eq-5d Health Profile (2012) (0)
Lung function abnormalities and their correlation with clinical characteristics and inflammatory markers in adult asthma. (2022) (0)
Staphylococcal enterotoxin specific IgE in serum is linked to severe asthma and nasal polyposis (2011) (0)
Olfactory Function Assessment (2022) (0)
Prospective Clinical Study of the Expression of the Cox-2 Gene in Nasal Polyposis (2004) (0)
Genetic variation in the toll-like receptor gene family and chronic rhinosinusitis: a GA2LEN pilot study (2011) (0)
Resumen ejecutivo de ARIA 2019: Vías integradas de atención para la rinitis alérgica en Argentina, España y México. (2019) (0)
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats (2020) (0)
In reply. (2013) (0)
IMPACT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS ON QUALITY OF LIFE BY SINO-NASAL SURGERY HISTORY (2018) (0)
Quality of and Psychological Burden (2022) (0)
MASK (Mobile Airways Sentinel Network), una app móvil con la solución integral de ARIA en países de habla hispana (2019) (0)
Alpha-1 antitrypsin deficiency associates with asthma exacerbations (2022) (0)
Subject Index Vol. 156, 2011 (2011) (0)
REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY Turner's syndrome and other forms of congenital hypogonadism impair quality of life and sexual function (2013) (0)
Multimorbidities (2022) (0)
Issue Information (2021) (0)
Is the Nasal Cycle Real? How Important Is It? (2020) (0)
Content Vol. 156, 2011 (2011) (0)
Mepolizumab Induced Loss of Smell Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps From the SYNAPSE Study (2022) (0)
Prevalence of asthma in Catalonia (Spain): a retrospective, large-scale population-based study. (2023) (0)
PPA_A_320242 2577..2586 (2021) (0)
P452 DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COMORBID ASTHMA: SINUS-24/SINUS-52 TRIALS (2019) (0)
IL5 Allergic Rhinitis in Europe (2012) (0)
Olfactory Dysfunction in Mental Illness (2023) (0)
MP-Azeflu Improves Quality of Life of Patients with Allergic Rhinitis: A Real-World Study (2020) (0)
Congestion Quantifier-7--Spanish Version (2017) (0)
133 Corticosteroid Rreatment Reduces Tissue Eosinophilia and the Expression of Matrix Metalloproteinases (MMP-1, MMP-2, MMP-7, MMP-9) and Their Tissue Inhibitor (TIMP-1) in Nasal Polyps (2012) (0)
MP-AzeFlu improves allergic rhinitis severity regardless of disease phenotype: a real-life study (2020) (0)
The Effect of Corticosteroids in Patients with Nasal Polyposis and Asthma (2004) (0)
Olfactory Training Prevents Olfactory Dysfunction Induced by Bulbar Excitotoxic Lesions: Role of Neurogenesis and Dopaminergic Interneurons (2019) (0)
Vasculitis Including Churg–Strauss Syndrome (2010) (0)
asthma . subjects and in patients with rhinitis and Response of the nose to exercise in healthy (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joaquim Mullol?

Joaquim Mullol is affiliated with the following schools:

Joaquim Mullol's Academic­Influence.com Rankings

Joaquim Mullol's Degrees

Similar Degrees You Can Earn

Why Is Joaquim Mullol Influential?

Joaquim Mullol's Published Works

Published Works

What Schools Are Affiliated With Joaquim Mullol?

Joaquim Mullol's AcademicInfluence.com Rankings